Introduction
Several review articles discussing the ability of HIV protease inhibitors to influence insulin sensitivity have been published within the last year [1] [2] [3] [4] [5] . Most of the previous discussions have appropriately considered the full spectrum of metabolic abnormalities encountered in the setting of highly active antiretroviral therapy (HAART). This includes the ability of HIV protease inhibitors to directly or indirectly alter body fat composition [6, 7] , lipid profiles [8] , adipocytokine levels [9] , and mediators of inflammation [10] . In addition, the potential for nucleoside reverse transcriptase inhibitor (NRTI)-induced changes in mitochondrial function to influence insulin sensitivity also has recently gained greater attention [11] . The complexity of antiretroviral regimens employed in clinical practice, including frequent changes in therapies, have hindered efforts to identify the direct effects of individual HIV protease inhibitors on tissuespecific and whole-body glucose homeostasis. However, in the search for safer antiretroviral agents, increased understanding of the direct molecular targets of HIV protease inhibitors offers great potential in ongoing efforts to design and test for newer generations of drugs that in addition to overcoming the problem of viral resistance also have improved safety profiles. This is particularly important given the expectations for longterm exposure to HIV protease inhibitors in the aging HIV-infected population. This review will focus primarily upon the most important recent studies that have been able to characterize the direct influence of individual HIV protease inhibitors on glucose homeostasis. The concordance of the evidence from various model systems (invitro, animal and healthy human volunteer) will be evaluated. When known, the specific cellular targets altered by these drugs will be discussed. This information will then be placed back into the context of antiretroviral treatment regimens in HIV-infected patients.
Clinically observed abnormalities in glucose homeostasis in relation to use of HIV protease inhibitor
The clinical use of HIV protease inhibitors in HIVpositive humans is clearly associated with the development of measurable changes in insulin sensitivity [12] . In many patients, when combined with underlying genetic risk, environmental factors, and other components of HAART, these changes are sufficient for the manifestation of overt diabetes mellitus [13, 14 ] . Although significant efforts to characterize the incidence, progression, and molecular mechanisms underlying this induction of insulin resistance continue, many questions still remain. It has become increasingly clear that individual protease inhibitors differ in their ability to induce insulin resistance in treated patients. The molecular and pharmacokinetic basis for these differences is only now beginning to be understood.
In much of the published clinical literature, 'insulin resistance' is considered as the net sum of alterations in each of the individual insulin responsive tissues (primarily liver, adipose tissue, and skeletal muscle) and changes in insulin secretion from pancreatic b cells. This is the result of the practicality of assessing glucose homeostasis via fasting blood sugar levels (which primarily reflect hepatic insulin sensitivity) and responses to an oral glucose challenge (which reflect both insulin secretion and peripheral glucose disposal). Many studies have relied upon indirect estimation of insulin sensitivity with tools such as homeostasis model assessment (HOMA) or quantitative insulin sensitivity check index (QUICKI). A growing number of studies have used the hyperinsulinemic euglycemic clamp technique, the established gold standard measure of insulin sensitivity. Euglycemic clamps, by their intrinsic design, do not assess b-cell function. Only a few studies [15, 16] have directly assessed pancreatic function in vivo using hyperglycemic clamps. The use of tracer dilution experiments to assess hepatic glucose production has also been reported in only a limited number of studies [16, 17] . The ability to identify differences in the abilities of individual HIV protease inhibitors to affect each of these tissues may allow tailoring of protease inhibitor-based treatment regimens based upon the molecular defects present.
Comparison of in-vitro effects of individual HIV protease inhibitors on insulin sensitivity
The use of an increasing number of in-vitro model systems has greatly assisted efforts to characterize the effects of individual protease inhibitors on insulin signaling and glucose transport. These studies have allowed study of cell-specific effects under static drug concentrations independent of systemic changes in homeostatic mechanisms. However, in the interpretation of these experiments, proper distinction needs to be made between acute versus chronic changes. Acute experiments (i.e. those occurring within minutes of drug exposure) are more likely to aid in the identification of direct molecular targets, whereas chronic treatment studies are more likely to mimic cellular changes that are observed in patient-treated populations. Both are important for the development of means to prevent or treat protease inhibitor-mediated insulin resistance.
The first few studies to establish that protease inhibitors (specifically indinavir, ritonavir, and amprenavir) are capable of acutely inducing insulin resistance were performed in cultured 3T3-L1 adipocytes and Xenopus oocytes, in which glucose transporter-4 (GLUT4) was identified as a direct target of indinavir [18] . These findings were later confirmed at physiologically relevant drug levels in primary rat adipocytes [19] . Additional tissues that have also shown HIV protease inhibitormediated insulin resistance in vitro include rat skeletal muscle (indinavir) [20] , L6 myocytes (nelfinavir, indinavir, saquinavir) [21] , HepG2 cells (nelfinavir and indinavir) [22] [23] [24] , human spontaneous baroreflex gain (SBG) adipocytes (ritonavir) [25] , and human subcutaneous adipocytes (lopinavir/ritonavir) [26] .
Even accounting for the varying concentrations of HIV protease inhibitors that were used in these studies, significant differences have been observed in the magnitude of the effects of individual drugs on glucose transport. Atazanavir (even with boosting levels of ritonavir) appears to have little to no effect on glucose uptake [26] . Studies in primary rat adipocytes have provided insights into the structural basis for these differences [27] . There is also evidence that some of the newer HIV protease inhibitors, in development, have little effect on glucose uptake. For example, in cultured adipocytes, the novel diethyl phosphonate-containing protease inhibitor GS-8374 does not acutely inhibit glucose uptake [28] .
There have been conflicting reports on the ability of HIV protease inhibitors to affect intracellular signaling pathways. Alterations in insulin signaling [such as insulin receptor substrate-1 (IRS-1) [25] and AKT [22] ] have been observed most frequently following chronic drug exposure (i.e. after hours to days) as opposed acute exposure (i.e. within minutes), which produces impaired glucose uptake despite normal signaling and GLUT4 translocation [18] . The differences that have been reported in the effects of HIV protease inhibitors on b-cell function can also be understood in consideration of the length of drug exposure [15, [29] [30] [31] [32] . Many of these studies also further reflect inherent differences between individual protease inhibitors, which may be due to either effects on distinct molecular targets or differing affinities for the same cellular proteins.
Although GLUT4 inactivation is an established primary mechanism by which some HIV protease inhibitors acutely alter glucose uptake in vitro [18] , the relationship between this effect and changes in other pathways is less clear. Reports that some of these drugs also inhibit the proteosome [1] have provided a potential link to the development of lipodystrophy and dyslipidemia, which are indirect contributors to insulin resistance. In addition, Ben-Romano et al. [33] have demonstrated in the 3T3-L1 model system that protease inhibitors (nelfinavir) induce oxidative stress. Lagathu et al. [34] have also provided evidence that the generation of reactive oxygen species (ROS), following 24-48 h exposure of cultured adipocytes to ritonavir, contribute to changes in inflammatory mediators and adipocytokine levels. In general, all these studies show a remarkable consistency in the differing effects of individual HIV protease inhibitors on insulin sensitivity. Specifically, indinavir and ritonavir appear to be the most toxic, whereas atazanavir is without effect.
Insights from rodent model systems
Correlation between these in-vitro effects and those observed in vivo has been provided by a number of studies in healthy lean rodents given HIV protease inhibitors acutely by intravenous infusion during hyperinsulinemic-euglycemic clamps. In addition to precise titration of steady-state serum drug levels, this model allows the investigation of protease inhibitor-mediated effects in a genetically and environmentally homogeneous background. The degree of insulin resistance induced in this model is in general agreement with the observations that have been made regarding the degree of impaired glucose uptake in vitro and insulin resistance observed in human patients. Specifically, indinavir, lopinavir, and ritonavir, each have been shown to produce the highest reductions in glucose disposal [35, 36] . In contrast, peripheral glucose disposal is not altered by either atazanavir or tipranavir under these same conditions [37] . Due to the acute nature of these experiments, compensatory changes in serum adipokine or lipid levels did not occur. In agreement with in-vitro data, GS-8374 also does not alter glucose disposal in this model [38 ] .
Underscoring the importance of underlying genetic risk, Carper et al. [39 ] have shown that in susceptible rodent (the Zucker rat), chronic administration of ritonavir resulted in an acceleration in the progression to overt diabetes. This was accompanied by detectable changes in TNF-a, Sterol regulatory element-binding protein 1 (SREBP-1), and insulin receptor substrate2 (IRS-2). Increased SOCS-1 expression was implicated in the pathogenesis of these effects.
The use of rodent models has also assisted in the evaluation of consequences of HIV protease inhibitormediated glucose transport blockade in insulinresponsive tissues. For instance, we have recently reported that ritonavir, but not atazanavir, acutely blocks glucose transport into rodent myocardium and that in the setting of heart failure this is accompanied by significant changes in contractile function [40] . In the future, the use of animal models with specific disruption or augmentation of cellular pathways, or both, implicated in the pathogenesis of protease inhibitor-mediated insulin resistance, is likely to provide more definitive evidence for the specific contribution of individual molecular targets.
Healthy human volunteer studies
The relevance of the in-vitro and animal model studies discussed above to human disease has been clearly demonstrated in the investigation of acute protease inhibitor-mediated changes in healthy HIV-negative human volunteers. Specifically, some, but not all, protease inhibitors have been shown to alter peripheral glucose disposal under hyperinsulinemic euglycemic clamp conditions. The earlier studies by Noor et al. [41] , which examined both 4-week and single-dose [42] treatment with indinavir, convincingly demonstrated significant reductions in glucose disposal. These studies have now been extended to look at additional protease inhibitors that are currently in widespread clinical use. These experiments have demonstrated that the effects of protease inhibitors on insulin sensitivity are not the same for all drugs within this class. Although full-dose ritonavir [43, 44 ] and lopinavir [45] are able to acutely induce insulin resistance in this model system, amprenavir [44 ] and atazanavir [46] are without effect. Again, attention to the duration of drug exposure is important in understanding the molecular basis for these observations. Although single dose [45] and 5 days of treatment [46] with lopinavir significantly reduced glucose disposal, no effect was found with 4 weeks of exposure to this HIV protease inhibitor [47] . These differences may be due to compensatory changes in adiponectin levels in the chronically treated patients [48] . This contrasts with the observation in HIV-positive patients with lipodystrophy that adiponectin levels are decreased [49] .
On the basis of in-vitro dose-response profiles of individual drugs, the differing propensities for the induction of peripheral insulin resistance with individual HIV protease inhibitors may be related at least in part by the serum drug levels achieved during treatment relative to the binding affinity of cellular targets such as GLUT4 [36] . Protease inhibitors in which the K d for GLUT4 and C max are similar will have significant effects on insulin sensitivity. With K d /C max ratios greater than 5-10, drug-induced changes in glucose disposal are likely to be minimal.
HIV-infected patients
A number of recent studies in HIV-infected patients have provided additional insight into the drug-specific effects of HIV protease inhibitors on insulin sensitivity and have added to the understanding that some, but not all, of the changes are reversible with changes in antiretroviral therapy (ART). For example, in the Lipostop study [50] , adipose tissue inflammation improved without detectable changes in fat mass within 6 months after withdrawal of therapy. Prospective analysis of treatmentnaïve patients started on HAART revealed that insulin resistance (as determined by HOMA) was significantly associated with the use of indinavir [51] . In this study, hepatitis C coinfection was also associated independently with the development of insulin resistance. Confirming the evidence from the previously discussed model systems that atazanavir has a more favorable metabolic profile, improvement in insulin sensitivity (as determined by euglycemic clamps) was demonstrated in HIVpositive men with dyslipidemia following the switch from stable HIV protease inhibitor-containing antiretroviral regimens to atazanavir/ritonavir [52 ] .
Validation of the role of implicated cellular mediators with reduced insulin sensitivity in HIV-infected patients is also continuing to emerge. For example, protease inhibitor-associated changes in markers of oxidative stress have been recently reported in HIV-infected patients [53] . In a recent long-term study comparing three different antiretroviral regimens [protease inhibitor, non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor þ NNRTI], insulin resistance was detected within 1 month only in the protease inhibitor-based group. However, after 5 years, the same degree of insulin resistance was also found in all three groups [7] . These latter effects, which were gradual and progressive, are likely mechanistically distinct from those observed with short-term protease inhibitor exposure.
As compensatory hyperinsulinemia allows the maintenance of euglycemia in the setting of peripheral insulin resistance, the progression to overt diabetes mellitus reflects the development of relative b-cell failure. The degree to which HIV protease inhibitors directly contribute to altered b-cell function in treated patients, as has been demonstrated in both in-vitro and rodent models, remains unclear. In the Swiss Cohort Study [14 ] , current use of protease inhibitor, both alone and in combination with NRTIs, was associated with an increased prevalence of diabetes, whereas cumulative exposure to these drugs was not. Examination of individual HIV protease inhibitors revealed that indinavir was most directly associated with diabetes. As with many of the clinical studies to date, power was not sufficient to determine significant changes with other individual protease inhibitors, although many did have a positive trend toward increased diabetes risk.
Although the utility of diagnosing patients with the 'metabolic syndrome' versus consideration of the individual components of this syndrome has been called into question both in the general population [54] and in HIVinfected patients [5] , the prospective INITIO trial has demonstrated that HIV-infected patients on ART who fulfill the criteria for having metabolic syndrome are at a significantly higher risk for progression to overt diabetes [55] . Although, in this study, no association between use of HIV protease inhibitors and the metabolic syndrome was found, significant correlations with protease inhibitor treatment have been reported by others [56] . The study by Mondy et al. [57] also failed to show a clear link between use of HIV protease inhibitor and 'metabolic syndrome'. As noted above, due to the number of different antiretroviral regimens used, limited statistical power with individual HIV protease inhibitors likely contributes to some of these differences. In addition, as insulin resistance does not necessarily coexist with the other components of the 'HIV-associated metabolic syndrome' [58] , showing definitive associations between individual protease inhibitors and insulin resistance in heterogeneous clinical populations is challenging. Nevertheless, these studies emphasize that traditional risk factors play a predominant role in the progression to impaired glucose tolerance.
Conclusion
In-vitro, animal model, and healthy human volunteer studies have greatly assisted efforts to understand the contribution of individual HIV protease inhibitors to the emergence of insulin resistance and overt diabetes mellitus in patients receiving protease inhibitors as part of HAART. Although these changes have been validated in many of the recent clinical studies, when compared with traditional risk factors and the influence of diseaserelated cellular changes (such as HIV infection itself or hepatitis C coinfection), the direct protease inhibitormediated effects on glucose homeostasis have been more difficult to identify and characterize. Thus, the ongoing use of in-vitro, animal, and healthy human volunteer studies will continue to aid efforts to prevent or treat protease inhibitor-induced effects on insulin sensitivity.
